ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
Pre-market 06:55:08 pm | |||
| 803.2 USD | +2.55% |
|
806.7 | +0.44% |
| 06:42am | Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment | MT |
| 06:27am | China Grants Green Light to Eli Lilly's Diabetes Treatment | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 43B 3,580B | Sales 2025 * | 52.61B 4,380B | Capitalization | 723B 60,208B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 993B | Net income 2025 * | 16.55B 1,378B | EV / Sales 2024 * | 17.3 x |
| Net Debt 2024 * | 19.98B 1,664B | Net Debt 2025 * | 15.29B 1,273B | EV / Sales 2025 * | 14 x |
| P/E ratio 2024 * |
60.1
x | P/E ratio 2025 * |
43.2
x | Employees | 43,000 |
| Yield 2024 * |
0.65% | Yield 2025 * |
0.75% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.48% | ||
| 1 week | +5.13% | ||
| Current month | +2.83% | ||
| 1 month | +10.58% | ||
| 3 months | +7.68% | ||
| 6 months | +35.53% | ||
| Current year | +37.78% |
1 week
766.12
816.61
1 month
718.30816.61
Current year
579.05816.61
1 year
419.80816.61
3 years
195.50816.61
5 years
101.36816.61
10 years
58.50816.61
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +8.99% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 803.2 | +2.55% | 4,334,499 |
| 20/24/20 | 783.2 | +1.71% | 2,188,818 |
| 17/24/17 | 770 | -0.15% | 1,670,317 |
| 16/24/16 | 771.1 | -2.02% | 2,299,653 |
| 15/24/15 | 787 | +3.02% | 3,038,253 |
Delayed Quote Nyse, May 22, 2024 at 01:30 am IST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.78% | 723B | |
| +30.94% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.06% | 244B | |
| +9.85% | 210B | |
| -4.91% | 208B | |
| +9.32% | 169B | |
| -0.80% | 162B |
- Stock Market
- Equities
- LLY Stock
